SUBSCRIBE
SUBSCRIBE
News   Drug Development

Study Shows Teva Pharmaceutical Industries Limited’s Laquinimod Slows MS

June 20, 2008 | 
1 min read

LONDON, June 20 (Reuters) - Teva Pharmaceutical Industries’ multiple sclerosis pill laquinimod appears to slow the disease and is well-tolerated by people with the relapsing form of the incurable condition, researchers said on Friday.

Clinical research Phase II Europe
MORE ON THIS TOPIC
Cardiovascular disease
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
April 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Climb up, hand help businessman build ladder
Diabetes
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
March 31, 2025
 · 
4 min read
 · 
Annalee Armstrong
World heart day. Sketch style human heart. Retro halftone hands reaching out to each other. Modern collage. Valentines day banner. Healthcare medical concept. Healthy lifestyle.
Cardiovascular disease
Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%
March 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Success roadmap journey, milestone or career path achievement, route or pathway to achieve goals, accomplishment, assessment or way to success, businessman look at achievement milestone to success.
GLP-1
Novo Paints Murky Cardio Picture for Semaglutide Franchise
March 31, 2025
 · 
2 min read
 · 
Tristan Manalac